Aktienanalyse zu Twist Bioscience Corp (TWST)TWSTTwist Bioscience Corp

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Twist Bioscience Corp is a good buy right now due to its current price of $141.38 being significantly lower than the analyst price target of $115, indicating potential upside. The company also shows a strong gross margin of 52.76% and has experienced a remarkable year-to-date change of +336.49%. However, the main risk is its negative earnings per share (EPS) of -0.56, indicating ongoing losses.

3 analysts cover TWST: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 41.25.